Details of the molecular interactions between GNF-2 and ABL001 and the... | Download Scientific Diagram
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
GME Antenna Base Universal with 4.5m Coaxial & PL259 - ABL001 - Accessories | Repco New Zealand
ABL-001 – A Branded Store
Asciminib (ABL001) | BCR-ABL1 Inhibitor | MedChemExpress
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Molecules | Free Full-Text | Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
ABL-001 | 1492952-76-7
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
ABL-001 – A Branded Store
ABL 001, Asciminib | New Drug Approvals
Asciminib | C20H18ClF2N5O3 | CID 72165228 - PubChem
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Asciminib (ABL001) | 99.88%(HPLC) | In Stock | Bcr-Abl inhibitor
eMolecules ABL-001 | 1492952-76-7 | | 5mg, Quantity: Each of 1 | Fisher Scientific
Asciminib, Supplier | ABL-001 | CAS 1492952-76-7 | ABL1 inhibitor | Sun-shinechem
ABL Bio
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.
ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.
ABL Bio
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram
